Back to top

crispr: Archive

Zacks Equity Research

Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.

VRTXNegative Net Change CRSPPositive Net Change

Zacks Equity Research

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

LLYPositive Net Change VRTXNegative Net Change ADCTPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?

Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.

REGNNegative Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy

Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.

SNYPositive Net Change VRTXNegative Net Change CRSPPositive Net Change

Zacks Equity Research

CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

VRTXNegative Net Change CRSPPositive Net Change SESNPositive Net Change